KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Halozyme Therapeutics (HALO) EBIT: 2009-2024

Historic EBIT for Halozyme Therapeutics (HALO) over the last 16 years, with Dec 2024 value amounting to $551.5 million.

  • Halozyme Therapeutics' EBIT rose 33.53% to $217.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $737.4 million, marking a year-over-year increase of 54.59%. This contributed to the annual value of $551.5 million for FY2024, which is 63.36% up from last year.
  • Per Halozyme Therapeutics' latest filing, its EBIT stood at $551.5 million for FY2024, which was up 63.36% from $337.6 million recorded in FY2023.
  • Over the past 5 years, Halozyme Therapeutics' EBIT peaked at $551.5 million during FY2024, and registered a low of $144.3 million during FY2020.
  • Moreover, its 3-year median value for EBIT was $337.6 million (2023), whereas its average is $385.5 million.
  • As far as peak fluctuations go, Halozyme Therapeutics' EBIT spiked by 313.36% in 2020, and later declined by 3.03% in 2022.
  • Over the past 5 years, Halozyme Therapeutics' EBIT (Yearly) stood at $144.3 million in 2020, then surged by 91.26% to $275.9 million in 2021, then fell by 3.03% to $267.5 million in 2022, then grew by 26.18% to $337.6 million in 2023, then spiked by 63.36% to $551.5 million in 2024.